News - Anti-Arthritics/Rheumatics, Licensing

Filter

Popular Filters

1 to 25 of 1207 results

Actavis settles Celebrex patent challenge with Pfizer

24-04-2014

Ireland-headquartered generic major Actavis has entered into an agreement with US pharma giant Pfizer…

ActavisAnti-Arthritics/RheumaticsCelebrexGenericsLegalPatentsPfizerUSA

Lupin inks strategic biosimilars joint venture agreement with Yoshindo

23-04-2014

Indian drugmaker Lupin has entered into a strategic joint venture agreement with Japanese pharma company,…

BiosimilarsBiotechnologyEnbrelInflammatory diseasesJapanLicensingLupinTakeda PharmaceuticalYoshindo

Epizyme earns $4 million milestone under GSK collaboration

22-04-2014

US clinical-stage biopharma firm Epizyme announced the achievement of the lead candidate milestone for…

BiotechnologyEpizymeFinancialGlaxoSmithKlineLicensingOncology

Sentinel Oncology in deal with Oncothyreon worth a potential $174 million

22-04-2014

UK-based small molecule drug discovered Sentinel Oncology has signed a collaboration agreement with the…

BiotechnologyLicensingOncologyOncothyreonResearchSentinel Oncology

Biogen Idec exercises option for Amunix’ XTENylated Factor VIII

21-04-2014

US privately-held biotech firm Amunix Operating says that Biogen Idec has exercised its option to enter…

AmunixBiogen IdecBiotechnologyHematologyLicensing

Teva and Pfizer settle patent litigation over Celebrex

17-04-2014

Israel-based Teva Pharmaceutical Industries says that its US subsidiary has settled a law suit with US…

Anti-Arthritics/RheumaticsCelebrexGenericsNorth AmericaPatentsPfizerTeva Pharmaceutical IndustriesUSA

Prosonix and Mylan in deal for Flixotide and Flovent generics

15-04-2014

Prosonix, a UK-based company which is developing a portfolio of inhaled “Respiratory Medicines by Design,”…

FloventGenericsGlaxoSmithKlineGlobalLicensingMylan LaboratoriesProsonixRespiratory and Pulmonary

Dutch biotech Mucosis partners with Chinese firm

Dutch biotech Mucosis partners with Chinese firm

15-04-2014

Dutch biotech company Mucosis has entered into a long-term collaboration and license agreement with China-based…

BiotechnologyChangchunChief executiveChinaDiseaseHuman respiratory syncytial virusLicensingMimopath technologyNetherlandsVaccines

RaQualia and Asahi Kasei Pharma progress their collaboration

RaQualia and Asahi Kasei Pharma progress their collaboration

14-04-2014

RaQualia Pharma says that its ongoing joint research with fellow Japanese drugmaker Asahi Kasei Pharma…

Asahi KaseiJapanLicensingPharmaceuticalRaQualia PharmaResearch

UAE’s Julphar inks five-year deal to market Merck & Co drugs

11-04-2014

United Arab Emirates-based drugmaker Julphar has signed a five-year licensing deal with US pharma giant…

JulpharLicensingMerck & CoPharmaceutical

Ampio’s Vyrix unit out-licenses certain rights for Zertane to Paladin

10-04-2014

USA-based biotech firm Ampio Pharmaceuticals says its wholly-owned subsidiary Vyrix Pharmaceuticals…

Ampio PharmaceuticalsBiotechnologyEndo Health SolutionsLicensingMen's HealthPaladin LabsVyrix PharmaceuticalsZertane

Express Scripts forecasts unsustainable increases in specialty drug spend in USA

Express Scripts forecasts unsustainable increases in specialty drug spend in USA

09-04-2014

Expensive treatments for broad patient populations are driving unprecedented growth in US spending on…

Anti-Arthritics/RheumaticsAnti-viralsMarkets & MarketingNorth AmericaOncologyPharmaceuticalPricingUSA

UK’s ValiRx forms joint venture to fast track lung cancer drug to Phase II

UK’s ValiRx forms joint venture to fast track lung cancer drug to Phase II

08-04-2014

UK biopharmaceutical company ValiRx has established ValiSeek, a joint venture company with Tangent Reprofiling.

Chief executiveLicensingLung cancerOncologyPharmaceuticalResearchScienceUKValiRxValiSeek

Almirall gains European rights to InDex Pharma’s Kappaproct

07-04-2014

Sweden’s InDex Pharmaceuticals and Spain’s largest drugmaker Almirall have signed a license agreement…

AlmirallEuropeGastro-intestinalsInDex PharmaceuticalsKappaproctLicensingPharmaceutical

Roche in deal with Oryzon to develop epigenetics-based medicines; Buys IQuum

Roche in deal with Oryzon to develop epigenetics-based medicines; Buys IQuum

07-04-2014

Swiss drug major Roche has entered to a worldwide collaboration with Spanish functional genomics firm…

BiotechnologyIQuumLicensingMergers & AcquisitionsOncologyORY-1001Oryzon GenomicsRoche

Amgen and GSK end marketing agreement for osteoporosis drug Prolia

Amgen and GSK end marketing agreement for osteoporosis drug Prolia

04-04-2014

World leading independent biotech firm Amgen revealed in a Securities and Exchange Commission filing…

AmgenAnti-Arthritics/RheumaticsBiotechnologyGlaxoSmithKlineLicensingProliaXgeva

Merck Serono in deal with Auxogyn to advance fertility research

03-04-2014

USA-based Auxogyn, a company dedicated to advancing women’s reproductive health, has entered into an…

AuxogynLicensingMerck KGaAMerck SeronoPharmaceuticalReproductive

Pharma is attracted to early-stage antibody deals in oncology

02-04-2014

Today, the top ten best-selling antibody therapeutics for cancer have accumulated revenues approaching…

BiotechnologyLicensingOncology

Second collaboration between FORMA Therapeutics and Celgene

02-04-2014

Privately-held drug discovery firm FORMA Therapeutics has entered a second strategic collaboration and…

BiotechnologyCelgeneFORMA TherapeuticsLicensingMergers & AcquisitionsResearch

Prasco to market the authorized generic of Lilly’s Evista in USA

01-04-2014

Privately-held US generics firm Prasco has signed a further deal with US pharma major Eli Lilly to market…

Anti-Arthritics/RheumaticsEli LillyEvistaGenericsMarkets & MarketingNorth AmericaPrasco LaboratoriesUSA

EMD Serono, Pfizer and Broad Institute link up on lupus research

EMD Serono, Pfizer and Broad Institute link up on lupus research

01-04-2014

EMD Serono, a US subsidiary of Germany’s Merck KGaA, has signed a research agreement with US pharma…

Anti-Arthritics/RheumaticsEMD SeronoMerck KGaAPfizerPharmaceuticalResearch

Otsuka acquires certain Dacogen and E7727 rights from Eisai

01-04-2014

Otsuka Pharmaceutical has reached an agreement with the US subsidiary of fellow Japanese drugmaker Eisai…

DacogenE7727EisaiLicensingOncologyOtsukaPharmaceutical

1 to 25 of 1207 results

Back to top